Glax­o­SmithK­line's vac­cines group aims for a first as it kicks off PhI­II RSV stud­ies

One of Glax­o­SmithK­line’s big projects at its glob­al vac­cine R&D cen­ter in Rockville, MD is set to en­ter Phase III af­ter pass­ing ear­ly-stage tests with fly­ing col­ors.

Eye­ing the wide-open res­pi­ra­to­ry syn­cy­tial virus (RSV) space, GSK is push­ing two dif­fer­ent vac­cine can­di­dates: GSK3888550A is de­signed to con­fer pro­tec­tion to in­fants via ma­ter­nal im­mu­niza­tion, while GSK3844766A is meant for the el­der­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.